Ceesay Abraham
SEC CIK 1722140 · EDGAR
BoughtSold
Most active insiders at RAPP, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Third Rock Ventures V, L.P. | 10% | — | $34.39M |
| 2 | Ceesay Abraham | CEO, Dir | — | $6.07M |
| 3 | Yeleswaram Krishnaswamy | Chief Development Off | — | $4.46M |
| 4 | Bredt David | CSO | — | $1.36M |
| 5 | Gault Cheryl | COO | — | $906.4K |
Transactions 24
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-24 16:05 | 2026-09-23 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $39.17 | -2,210 | 456.8K | -0.5% | -$86.6K |
| MT | 2026-09-09 16:05 | 2026-09-08 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $45.61 | -8,210 | 459.0K | -2% | -$374.5K |
| T | 2026-08-26 16:05 | 2026-08-25 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $49.57 | -18.9K | 467.2K | -4% | -$938.0K |
| MT | 2026-08-12 16:35 | 2026-08-10+ | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $47.25 | -51.5K | 486.1K | -10% | -$2.43M |
| MT | 2026-07-29 16:05 | 2026-07-27 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $42.11 | -2,210 | 537.6K | -0.4% | -$93.1K |
| MT | 2026-07-15 16:15 | 2026-07-14 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $40.00 | -8,210 | 539.8K | -1% | -$328.4K |
| MT | 2026-07-01 16:05 | 2026-06-29 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $39.83 | -8,220 | 548.0K | -1% | -$327.4K |
| 2026-05-11 16:51 | 2026-05-08 | CRL | Charles River Laboratories | Ceesay Abraham | Dir | A - Grant | $177.62 | +1,438 | 2,384 | +152% | +$255.4K | |
| MT | 2026-02-19 | 2026-02-18 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $29.34 | -5,833 | 556.2K | -1% | -$171.2K |
| MTI | 2026-02-19 | 2026-02-18 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $29.35 | -5,083 | 22.8K | -18% | -$149.2K |
| TI | 2026-01-22 | 2026-01-20 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $26.11 | -5,083 | 25.8K | -16% | -$132.7K |
| T | 2026-01-22 | 2026-01-20 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $26.12 | -5,833 | 562.1K | -1% | -$152.4K |
| MT | 2025-12-18 | 2025-12-17 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $29.64 | -5,833 | 567.9K | -1% | -$172.9K |
| MTI | 2025-12-18 | 2025-12-17 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $29.63 | -5,083 | 33.8K | -13% | -$150.6K |
| MTI | 2025-11-18 | 2025-11-17 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $25.21 | -5,083 | 36.0K | -12% | -$128.1K |
| MT | 2025-11-18 | 2025-11-17 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $25.19 | -5,833 | 576.8K | -1% | -$146.9K |
| MT | 2025-10-16 | 2025-10-15 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $25.81 | -5,833 | 580.8K | -1.0% | -$150.5K |
| MTI | 2025-10-16 | 2025-10-15 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $25.81 | -5,083 | 41.1K | -11% | -$131.2K |
| MT | 2025-09-19 | 2025-09-17 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $26.32 | -40.8K | 585.4K | -7% | -$1.07M |
| MTI | 2025-09-19 | 2025-09-17 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO, Dir | S - Sale | $26.31 | -35.6K | 46.1K | -44% | -$936.4K |
| 2025-09-08 | 2025-09-04 | PCRX | Pacira BioSciences, Inc. | Ceesay Abraham | Dir | S - Sale | $27.19 | -2,354 | 9,039 | -21% | -$64.0K | |
| D | 2025-06-13 | 2025-06-11 | PCRX | Pacira BioSciences, Inc. | Ceesay Abraham | Dir | A - Grant | $0.00 | +6,163 | 11.4K | +118% | $0 |
| D | 2025-06-04 | 2025-06-02 | CRL | Charles River Laboratories | Ceesay Abraham | Dir | A - Grant | $135.04 | +946 | 946 | New | +$127.7K |
| D | 2024-06-13 | 2024-06-12 | PCRX | Pacira BioSciences, Inc. | Ceesay Abraham | Dir | A - Grant | $0.00 | +5,230 | 5,230 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations